| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aac4a747e60a2949ac458ccdbb76fdea |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-608
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-61 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-82 |
| filingDate |
2011-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46f83a23276ac294c4d9bc443c054bdc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41cbe7b093fcd23e19fe70b8618960ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_306a212ff074458afe717a5b3d5e167d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d43f27be30923d262037c05c3d1a8715 |
| publicationDate |
2013-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20130131373-A |
| titleOfInvention |
Local Vascular Delivery of Adenosine A2A Receptor Agonists / Phosphodiesterase Inhibitor Combinations to Reduce Myocardial Injury |
| abstract |
Stents or other implantable medical devices for topical delivery of selective adenosine receptor agonists may be used in combination with other therapeutic agents to reduce myocardial damage following acute myocardial infarction. As soon as possible after acute myocardial infarction, a stent or other suitable device containing a selective adenosine receptor agonist and capable of delivering the agonist is placed in the vessel with the occlusion causing the infarction. Once in place, the stent or other luminal device is placed such that the occlusion is removed and blood flow to a particular region, area or tissue volume of the heart is reestablished. Over a given time, selective adenosine receptor agonists, alone or in combination with other therapeutic agents, elute into hypoxic heart tissue from the stent or other device into the coronary blood flow downstream from the stent or other device for a time sufficient to reduce the level of myocardial damage. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220088945-A |
| priorityDate |
2010-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |